Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service structural heart (TAVR, TEER) cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 83 | 40% |
| 2020 | 9 | 99 | 43% |
| 2021 | 7 | 91 | 46% |
Transcatheter aortic valve replacement and mitral edge-to-edge repair. Professional codes (what the surgeon bills): CPT 33361, 33362, 33363, 33364, 33365, 33366, 33418, 33419; the hospital bills MS-DRG 266, 267.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Mexico; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 238 | 5,995+3.6%/yr | +3.6%/yr | 1.5 | 0% | 8,310 in 2030+5.6%/yr |
| Washington | 65 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 18 | 1,021−9%/yr | −9%/yr | 3.60.8× | 0% | 1,030 in 2030+0.2%/yr |
| Mechanical circulatory support |
Structural heart (TAVR, TEER) in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
| ≈ 170 |
| – |
| 2026 est. | ≈ 180 | – |
| 2022 | 6 | 124 | 50% |
| 2023 | 8 | 175 | 53% |
| 2024 | 9 | 207 | 54% |
| 2025 from claims | – | 171 138–200 | 54% |
| 2026 forecast | – | 185 145–232 | 55% |
| 2027 forecast | – | 202 150–267 | 55% |
| 2028 forecast | – | 220 156–304 | 56% |
| 2029 forecast | – | 240 163–345 | 56% |
| 2030 forecast | – | 262 172–389 | 56% |
In 2025, 100% inpatient hospital.
| 1,756+5.4%/yr |
| +5.4%/yr |
| 1.9 |
| 0% |
| 2,430 in 2030+5.5%/yr |
| Arizona | 74 | 1,643+5.5%/yr | +5.5%/yr | 1.9 | 0% | 2,270 in 2030+5.5%/yr |
| Oregon | 39 | 802+2.6%/yr | +2.6%/yr | 1.6 | 0% | 1,140 in 2030+6%/yr |
| Colorado | 33 | 787+4.2%/yr | +4.2%/yr | 1.3 | 0% | 1,130 in 2030+6.3%/yr |
| Nevada | 30 | 487+4.8%/yr | +4.8%/yr | 1.4 | 0% | 610 in 2030+3.7%/yr |
| Utah | 21 | 422−1.7%/yr | −1.7%/yr | 1.6 | 0% | 410 in 2030−0.3%/yr |
| Montana | 15 | 357+1.6%/yr | +1.6%/yr | 1.7 | 0% | 480 in 2030+5.2%/yr |
| Idaho | 17 | 257+2.2%/yr | +2.2%/yr | 1.1 | 0% | 530 in 2030+13%/yr |
| Alaska | 5 | 100+16%/yr | +16%/yr | 0.8 | 0% | 190 in 2030+11%/yr |
| 2 |
| 123−0.2%/yr |
| −0.2%/yr |
| 0.51.2× |
| 0% |
| 80 in 2030−6.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 45% of company spending on these surgeons in 2025, +36 pts on 2024.
In 2025, 5 companies reported engagement with New Mexico’s surgeons worth $90K in consulting, speaking, meals and travel tied to these products, about $9,968 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 52 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.